"""
Question: 1101 

Evidence: This was a multicenter, longitudinal, observational study with retrospective patient enrolment. Overall, 459 patients were enrolled and 329 completed 24 months of treatment.

Rationale: The paper describes a newly conducted observational study with prospectively defined outcomes and reports enrollment numbers and results, indicating it presents original, previously unpublished clinical data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. Data presentation is purely descriptive.

Rationale: The paper reports aggregate genotyping results (mutation detection) rather than providing primary sequence data; there are no mentions of sequence deposition or sequence listings, indicating no HIV sequences are reported.

Answer: No
"""

"""
Question: 1103 

Evidence: This was a multicenter, longitudinal, observational study with retrospective patient enrolment. There were no protocol-specified procedures and patients were followed up according to the usual procedure followed by the physician for two years.

Rationale: The study design is clinical and observational without laboratory experimental procedures; there is no mention of in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. Data presentation is purely descriptive.

Rationale: The paper reports genotypic (sequence-based) resistance information only and does not present any phenotypic susceptibility assays or IC values, indicating no in vitro antiretroviral susceptibility data.

Answer: No
"""

"""
Question: 2101 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. Data presentation is purely descriptive.

Rationale: The manuscript documents genotyping results but does not report any sequence depositions or accession numbers, hence no GenBank accession numbers are provided.

Answer: No
"""

"""
Question: 2102 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. Data presentation is purely descriptive.

Rationale: As no GenBank accession numbers are reported at all, there are none for clinical (non-laboratory) isolates.

Answer: No
"""

"""
Question: 2103 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. Data presentation is purely descriptive.

Rationale: The paper does not list any accession numbers; therefore, none can be provided.

Answer: NA
"""

"""
Question: 2202 

Evidence: Nine out of 150 patients (6%) presented a DTG resistance mutation before starting the DTG regimen. These mutations are listed in Table 4.

Rationale: The paper provides aggregated mutation findings and representative mutation lists in Table 4 but does not provide per-sample, per-individual mutation lists linked to specific isolates.

Answer: No
"""

"""
Question: 2301 

Evidence: Adult HIV-1-infected patients experiencing treatment failure, who were starting DTG for the first time between February 2014 and September 2016, were eligible.

Rationale: The inclusion criteria explicitly identify the species as HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Adult HIV-1-infected patients experiencing treatment failure, who were starting DTG for the first time between February 2014 and September 2016, were eligible. In addition, results of any genotyping to evaluate resistance mutations were documented.

Rationale: Although the species (HIV-1) is given, the paper does not report viral subtypes for sequenced viruses.

Answer: NA
"""

"""
Question: 2303 

Evidence: At inclusion, 179 of 349 patients tested (51.3%) presented at least one resistance mutation for nucleoside reverse transcriptase inhibitors (NRTIs). Resistance mutations for non-nucleoside reverse transcriptase inhibitors (NNRTIs) were detected in 154/350 tested patients (44.0%) and resistance mutations for protease inhibitors (PIs) in 139/349 tested patients (39.8%). Nine out of 150 patients (6%) presented a DTG resistance mutation before starting the DTG regimen.

Rationale: The resistance classes reported correspond to the pol gene regions sequenced for genotyping: reverse transcriptase (NRTI/NNRTI), protease (PI), and integrase (DTG resistance), indicating PR, RT, and IN regions of pol.

Answer: Protease, Reverse Transcriptase, Integrase
"""

"""
Question: 2304 

Evidence: Resistance mutations for non-nucleoside reverse transcriptase inhibitors (NNRTIs) were detected in 154/350 tested patients (44.0%) and resistance mutations for protease inhibitors (PIs) in 139/349 tested patients (39.8%). Nine out of 150 patients (6%) presented a DTG resistance mutation before starting the DTG regimen.

Rationale: The detection of resistance mutations in protease, reverse transcriptase, and integrase implies results from HIV pol sequencing were reported.

Answer: Yes
"""

"""
Question: 2401 

Evidence: COPEDOL was a multicenter, longitudinal observational study conducted in hospitals treating PLWHIV in France.

Rationale: The study location indicates the geographic origin of patient samples and genotyping data as France.

Answer: France
"""

"""
Question: 2402 

Evidence: Patients were enrolled between February 2017 and January 2018. Patients starting DTG treatment between February 2014 and September 2016 were retrospectively included.

Rationale: Although the study specifies enrollment and treatment initiation windows, it does not explicitly state the years when sequencing/genotyping samples were obtained; thus exact years for sequencing cannot be determined.

Answer: NA
"""

"""
Question: 2502 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. Resistance mutations were defined according to the ANRS classification algorithm [6].

Rationale: The sequencing method (e.g., Sanger) is not specified in the text; only that genotyping was performed and interpreted via ANRS criteria.

Answer: NA
"""

"""
Question: 2503 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. Resistance mutations were defined according to the ANRS classification algorithm [6].

Rationale: The paper does not indicate the use of an NGS platform for sequencing.

Answer: NA
"""

"""
Question: 2504 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. There were no protocol-specified procedures and patients were followed up according to the usual procedure followed by the physician for two years.

Rationale: The manuscript does not mention cloning of samples prior to sequencing.

Answer: NA
"""

"""
Question: 2505 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. There were no protocol-specified procedures and patients were followed up according to the usual procedure followed by the physician for two years.

Rationale: Single-genome sequencing is not described in the methods.

Answer: NA
"""

"""
Question: 2506 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. There were no protocol-specified procedures and patients were followed up according to the usual procedure followed by the physician for two years.

Rationale: The paper does not report molecular cloning.

Answer: NA
"""

"""
Question: 2601 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. In keeping with the observational nature of the study, there were no protocol-specified procedures.

Rationale: The source of viral nucleic acid (plasma RNA vs. cellular DNA) for genotyping is not specified.

Answer: NA
"""

"""
Question: 2602 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. In keeping with the observational nature of the study, there were no protocol-specified procedures.

Rationale: The study does not specify PBMC-derived sequencing.

Answer: NA
"""

"""
Question: 2603 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. In keeping with the observational nature of the study, there were no protocol-specified procedures.

Rationale: The number of plasma virus sequences is not reported.

Answer: NA
"""

"""
Question: 2604 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. In keeping with the observational nature of the study, there were no protocol-specified procedures.

Rationale: The number of PBMC virus sequences is not reported.

Answer: NA
"""

"""
Question: 2605 

Evidence: Patients were stratified into two groups according to the failure reason of the previous ART. The virological failure (VF) group corresponded to patients with virological failure (on-treatment viral load ≥ 50 copies/mL) and the toxicity (TOX) group to those failing due to adverse events (AE).

Rationale: Although many patients had active viremia, the paper does not specify from which compartment sequencing was performed; therefore, whether sequences came from actively replicating virus cannot be definitively determined.

Answer: NA
"""

"""
Question: 2606 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. In keeping with the observational nature of the study, there were no protocol-specified procedures.

Rationale: The manuscript does not state that genotyping was performed on proviral DNA; thus this cannot be determined.

Answer: NA
"""

"""
Question: 2701 

Evidence: Adult HIV-1-infected patients experiencing treatment failure, who were starting DTG for the first time between February 2014 and September 2016, were eligible.

Rationale: Only adults were included; there were no infants or children.

Answer: No
"""

"""
Question: 2702 

Evidence: Patients participating in a clinical trial were not eligible.

Rationale: The study explicitly excluded clinical trial participants.

Answer: No
"""

"""
Question: 2703 

Evidence: Patients participating in a clinical trial were not eligible.

Rationale: Because trial participants were excluded, none of the individuals were in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: At inclusion, 179 of 349 patients tested (51.3%) presented at least one resistance mutation for nucleoside reverse transcriptase inhibitors (NRTIs). Nine out of 150 patients (6%) presented a DTG resistance mutation before starting the DTG regimen.

Rationale: Different subsets were genotyped for different regions, and the paper does not provide a single, unified count of individuals with sequencing; thus the exact number of individuals with sequencing cannot be determined.

Answer: NA
"""

"""
Question: 3102 

Evidence: For the 311 patients for whom genotyping was available, over one quarter only had one drug option left according to the Genotypic Sensitivity Score (GSS). At inclusion, 179 of 349 patients tested (51.3%) presented at least one resistance mutation for nucleoside reverse transcriptase inhibitors (NRTIs).

Rationale: Since genotyping was not available for all 459 participants, not all individuals underwent HIV sequencing/genotyping.

Answer: No
"""

"""
Question: 4101 

Evidence: Adult HIV-1-infected patients experiencing treatment failure, who were starting DTG for the first time between February 2014 and September 2016, were eligible. The mean ART treatment duration was 13 ± 7 years.

Rationale: The cohort consisted of pretreated patients with prior ART exposure; no ART-naive individuals are described.

Answer: No
"""

"""
Question: 4102 

Evidence: The mean ART treatment duration prior to inclusion was 13 years and patients had already been exposed to seven ART treatment lines on average before starting DTG. Previous ART class exposure included NRTI, NNRTI, Protease inhibitor, and Integrase inhibitor.

Rationale: The study population was ART-experienced, and genotyping data came from these individuals.

Answer: Yes
"""

"""
Question: 4103 

Evidence: Adult HIV-1-infected patients experiencing treatment failure, who were starting DTG for the first time between February 2014 and September 2016, were eligible. The mean ART treatment duration prior to inclusion was 13 years.

Rationale: Only ART-experienced individuals were included; therefore, the study did not include ART-naive individuals.

Answer: No
"""

"""
Question: 4104 

Evidence: Adult HIV-1-infected patients experiencing treatment failure, who were starting DTG for the first time between February 2014 and September 2016, were eligible. The mean ART treatment duration prior to inclusion was 13 years.

Rationale: No ART-naive individuals were enrolled; hence zero samples from ART-naive individuals.

Answer: 0
"""

"""
Question: 4105 

Evidence: The previous ART regimen was most frequently a triple therapy, accounting for > 85% of cases in the TOX group. A large number of different ARTs were used in combination with DTG in the treatment regimens, and these ARTs could change over the course of the study; this heterogeneity could have an impact on the observed treatment outcomes.

Rationale: The paper provides summarized prior regimen classes and examples but does not give a complete, individual-level ART history for every participant.

Answer: No
"""

"""
Question: 4201 

Evidence: Adult HIV-1-infected patients experiencing treatment failure, who were starting DTG for the first time between February 2014 and September 2016, were eligible. In addition, results of any genotyping to evaluate resistance mutations were documented.

Rationale: The study focuses on treatment-experienced patients and does not assess transmitted drug resistance prevalence among newly infected or ART-naive individuals.

Answer: No
"""

"""
Question: 4202 

Evidence: Adult HIV-1-infected patients experiencing treatment failure, who were starting DTG for the first time between February 2014 and September 2016, were eligible. In addition, results of any genotyping to evaluate resistance mutations were documented.

Rationale: The study does not examine pretreatment drug resistance prior to first ART; it examines resistance at the time of switch among pretreated individuals.

Answer: No
"""

"""
Question: 4301 

Evidence: Previous ART class exposure included NRTI, NNRTI, Protease inhibitor, Fusion inhibitor, Entry inhibitor (CCR5 antagonist), Integrase inhibitor. The previous ART regimen was most frequently a triple therapy.

Rationale: The text explicitly lists prior drug classes used by participants.

Answer: NRTI, NNRTI, Protease inhibitor, Integrase inhibitor, Fusion inhibitor, Entry inhibitor (CCR5 antagonist)
"""

"""
Question: 4302 

Evidence: Integrase inhibitor 99 (44.6%) in the VF group and 51 (21.5%) in the TOX group. Dolutegravir (DTG) is a second-generation INSTI.

Rationale: The paper reports prior exposure to integrase inhibitors and describes dolutegravir use.

Answer: Yes
"""

"""
Question: 4303 

Evidence: Protease inhibitor 192 (86.5%) in the VF group and 175 (73.8%) in the TOX group. The most frequently used combinations were two nucleoside reverse transcriptase inhibitors with a protease inhibitor.

Rationale: The manuscript reports that many individuals had received protease inhibitors.

Answer: Yes
"""

"""
Question: 4304 

Evidence: In the VF group, ART regimens were much more varied. During the two-year follow-up period, 250 patients (54.7%) remained on the same DTG treatment regimen and 207 (45.3%) changed treatment regimen.

Rationale: There was substantial heterogeneity in regimens; therefore, not all individuals received the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: Previous ART class exposure included Integrase inhibitor. The number of treatment options left at inclusion was limited, with a GSS score < 1 in one-third of patients.

Rationale: Many participants had previously received INSTIs; thus, the cohort was not entirely INSTI-naive.

Answer: No
"""

"""
Question: 4403 

Evidence: The mean ART treatment duration prior to inclusion was 13 years and patients had already been exposed to seven ART treatment lines on average before starting DTG. Median [range] number of previous ART lines was 7 [1–39] in the VF group and 4 [1–30] in the TOX group.

Rationale: Although it is clear that many had multiple regimens, the exact count of individuals with more than one regimen is not explicitly provided.

Answer: NA
"""

"""
Question: 4404 

Evidence: The mean ART treatment duration prior to inclusion was 13 years and patients had already been exposed to seven ART treatment lines on average before starting DTG. Median [range] number of previous ART lines was 7 [1–39] in the VF group and 4 [1–30] in the TOX group.

Rationale: The distribution shows many had more than two regimens, but the exact number is not explicitly stated.

Answer: NA
"""

"""
Question: 4405 

Evidence: Median [range] number of previous ART lines was 7 [1–39] in the VF group and 4 [1–30] in the TOX group. The previous ART regimen was most frequently a triple therapy.

Rationale: The wide ranges in number of previous ART lines indicate individuals did not all receive the same number of regimens.

Answer: No
"""

"""
Question: 4406 

Evidence: Median [range] number of previous ART lines was 7 [1–39] in the VF group and 4 [1–30] in the TOX group. The mean ART treatment duration prior to inclusion was 13 years.

Rationale: The ranges and long treatment durations indicate that many had more than one regimen; therefore not all received just one regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: The remaining 459 patients constituted the study population. The study was conducted by hospital physicians with experience in treating PLWHIV who had been prescribed DTG.

Rationale: All enrolled participants were prescribed dolutegravir as part of the study objectives.

Answer: 459
"""

"""
Question: 4502 

Evidence: In the VF group, ART regimens were much more varied. The most frequently used combinations were two nucleoside reverse transcriptase inhibitors with a protease inhibitor.

Rationale: Table 2 shows DTG-containing regimens explicitly listing darunavir/ritonavir in two rows (DTG + DRV + RTV and DTG + FTC/TDF + DRV + RTV) totaling 46 individuals; other “Other” categories are unspecified, so 46 is the count explicitly reported.

Answer: 46
"""

"""
Question: 5101 

Evidence: At inclusion, 179 of 349 patients tested (51.3%) presented at least one resistance mutation for nucleoside reverse transcriptase inhibitors (NRTIs). Resistance mutations for non-nucleoside reverse transcriptase inhibitors (NNRTIs) were detected in 154/350 tested patients (44.0%) and resistance mutations for protease inhibitors (PIs) in 139/349 tested patients (39.8%).

Rationale: The paper provides per-class counts but does not provide a deduplicated total of individuals with at least one mutation across any class; therefore, the overall number cannot be determined from the provided text.

Answer: NA
"""

"""
Question: 5102 

Evidence: Nine out of 150 patients (6%) presented a DTG resistance mutation before starting the DTG regimen. Five patients acquired DTG resistance mutations.

Rationale: Summing baseline and emergent cases indicates 14 individuals with INSTI-resistance mutations reported in the study.

Answer: 14
"""

"""
Question: 5103 

Evidence: At inclusion, 179 of 349 patients tested (51.3%) presented at least one resistance mutation for nucleoside reverse transcriptase inhibitors (NRTIs). Resistance mutations were summarized by class; specific TDF-associated mutations were not enumerated.

Rationale: The paper does not break down NRTI resistance by specific drugs like TDF; thus the number with TDF-resistance mutations is not reported.

Answer: NA
"""

"""
Question: 5104 

Evidence: These mutations are listed in Table 4. These were mainly Q148H/K/R mutations, either alone or associated with other mutations.

Rationale: The paper states that five patients acquired dolutegravir resistance mutations and refers to Table 4 for the specific mutations; the mutations reported at the end of the study include Q148H/K/R, G140A/C/S, N155H, E92Q+N155H, V151L, R263K, S153F, E157Q, E138A/K/T, and T66K+L74M.

Answer: Q148H/K/R (often with G140A/C/S and/or L74I and/or E138A/K/T), G140A/C/S, N155H, E92Q+N155H, V151L, R263K, S153F, E157Q, E138A/K/T, T66K+L74M
"""

"""
Question: 6101 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. Data presentation is purely descriptive.

Rationale: No phenotypic susceptibility testing methods are described in the paper.

Answer: NA
"""

"""
Question: 6102 

Evidence: Data presentation is purely descriptive. In addition, results of any genotyping to evaluate resistance mutations were documented.

Rationale: The paper does not report IC50 or IC90 values.

Answer: No
"""

"""
Question: 6103 

Evidence: Data presentation is purely descriptive. In addition, results of any genotyping to evaluate resistance mutations were documented.

Rationale: No IC50 fold change values are presented.

Answer: No
"""

"""
Question: 6104 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. Data presentation is purely descriptive.

Rationale: No phenotypic susceptibility assay is reported.

Answer: NA
"""

"""
Question: 6105 

Evidence: Data presentation is purely descriptive. Safety outcomes included on-treatment AEs, standard laboratory tests, body weight, discontinuation or modification of DTG treatment for safety reasons and pregnancies.

Rationale: Replication capacity data are not reported.

Answer: No
"""

"""
Question: 6106 

Evidence: In addition, results of any genotyping to evaluate resistance mutations were documented. Data presentation is purely descriptive.

Rationale: No phenotypic susceptibility testing was performed; hence no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: This was a multicenter, longitudinal, observational study with retrospective patient enrolment. In addition, results of any genotyping to evaluate resistance mutations were documented.

Rationale: The paper does not describe constructing site-directed mutant isolates; it reports patient-derived genotypes only.

Answer: No
"""

"""
Question: 7102 

Evidence: This was a multicenter, longitudinal, observational study with retrospective patient enrolment. There were no protocol-specified procedures and patients were followed up according to the usual procedure followed by the physician for two years.

Rationale: No in vitro passage experiments are described.

Answer: No
"""